Contact this trialFirst, we need to learn more about you.
PD-1 Inhibitor
Neoantigen Vaccine + Pembrolizumab for Follicular Lymphoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new type of FL vaccine which may be a treatment for follicular lymphoma. The agents used in this study are Rituximab, a personalized NeoAntigen vaccine, Poly-ICLC, and Pembrolizumab.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service